Publications by authors named "Javier Queiruga-Parada"

Claim this Profile
P
Population PK Modeling of Denosumab Biosimilar MB09 and Reference Denosumab to Establish PK Similarity.
Sara Sánchez-Vidaurre, Alexandra Paravisini, Javier Queiruga-Parada

Pharmaceutics· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete

Vaccine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects.
Monika Tomaszewska-Kiecana, Elisabete Carapuça, Amalia Florez-Igual, Javier Queiruga-Parada

Clin Transl Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210).
Cristina Ferreras, Clara Hernández-Blanco, Alejandro Martín-Quirós, Karima Al-Akioui-Sanz, Marta Mora-Rillo, Javier Queiruga-Parada

Cytotherapy· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete

Lancet Reg Health Eur· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.
Rocío Montejano, Fernando de la Calle-Prieto, María Velasco, Carlos Guijarro, Javier Queiruga-Parada

Clin Infect Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial.
Irene García-García, Enrique Seco-Meseguer, Pilar Ruiz-Seco, Gema Navarro-Jimenez, Raúl Martínez-Porqueras, Javier Queiruga-Parada

J Clin Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
Irene García García, Miguel Rodriguez-Rubio, Amelia Rodríguez Mariblanca, Lucía Martínez de Soto, Lucía Díaz García

Trials· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis